GlassScriptPhysician profile
Bryan Jay Daines
NPI 1679212443
$8,856.90
in general payments reported to CMS, 2019-2025
24 companies · $2,703 in 2025
The $2,703 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $571 · 2023: $2,257 · 2024: $3,326 · 2025: $2,703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,086 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,085.61 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,173.90 | 2022-2025 | Rinvoq |
| Dermavant Sciences, INC. | $935.16 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $896.39 | 2022-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $859.16 | 2023-2025 | |
| Janssen Biotech, INC. | $732.27 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Ucb, INC. | $716.05 | 2023-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $417.95 | 2024-2025 | Nemluvio |
| Lilly USA, LLC | $375.25 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Leo Pharma INC. | $351.66 | 2024-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $337.82 | 2022-2024 | Sotyktu |
| Incyte Corporation | $327.41 | 2023-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $292.25 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.16 | 2023-2025 | Spevigo |
| Arcutis Biotherapeutics, INC. | $243.54 | 2023 | |
| Sun Pharmaceutical Industries INC. | $239.20 | 2022-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $169.14 | 2024-2025 | |
| Kerecis Limited | $139.46 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Biofrontera INC. | $132.66 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Journey Medical Corporation | $59.72 | 2023-2025 | |
| Almirall LLC | $52.78 | 2024 | Klisyri, Seysara |
| Organogenesis INC. | $47.08 | 2024 | Puraply Am |
| Kyowa Kirin, INC. | $40.93 | 2025 | |
| Janssen Scientific Affairs, LLC | $33.35 | 2023 | Tremfya |
| Mayne Pharma Commercial LLC | $22.61 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Daines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.